SULFOXIMINES

Construction of a sulfoximine group has been found as an utile approach in medicinal chemistry to improve ADME/Tox profile and to enhance potency of the biologically active compounds. The moiety of sulfoximine is chemically and metabolically stable. *NH*-sulfoximines can serve as the both hydrogen bond donors and acceptors at the same time. Production and commercialization of the building blocks that already contain sulfoximine group allow significant accelerating discovery of drug candidates.



CDK inhibitor
WO 2011/120922
Bayer



Crop protection
WO 2006/037945
Syngenta



ATR inhibitor
WO 2011/154737
AstraZeneca



MNKK inhibitor
WO 2014/072244
Boehringer Ingelheim



Sulfoxaflor (crop protection)
US 2009/23782
Dow AgroSciences

Properties





- stable to hydrolysis
- increases aqueous solubility
- can be modified at *NH*
- *NH*-sulfoximines serve as H-bond donors and acceptors

Our offer: >200 Sulfoximine building blocks in gram amounts in stock
Custom synthesis of further analogues and compound libraries



References

[1] M. Frings, C. Bolm, A. Blum. *Eur. J. Med. Chem.* **2017**, 225.
[2] U. Lücking. *Angew. Chem. Int. Ed.* **2013**, 9399.
[3] S. Park, H. Buschmann, C. Bolm. *Bioorg. Med. Chem. Lett.* **2011**, 4888.
[4] T. Toru, C. Bolm. *Organosulfur Chemistry in Asymmetric Synthesis*, **2008**, 209.